By Mill Chart
Last update: Aug 14, 2025
VENUS CONCEPT INC (NASDAQ:VERO) reported its second-quarter 2025 financial results, revealing mixed performance relative to analyst expectations. The medical aesthetics technology company posted revenue of $15.69 million, surpassing the consensus estimate of $14.9 million. However, its earnings per share (EPS) came in at -$8.03, significantly worse than the anticipated -$6.67.
The earnings announcement reiterated Venus Concept’s position as a global leader in medical aesthetic technology, with a product portfolio spanning minimally invasive and non-invasive treatments. The company highlighted its continued expansion across more than 60 countries, though no specific forward-looking guidance was provided in the press release.
Looking ahead, analysts project:
The lack of an official outlook from management leaves investors reliant on these estimates, which suggest persistent challenges in profitability despite steady sales growth.
While Venus Concept’s revenue outperformed expectations, the widening losses raise concerns about the company’s path to profitability. The muted after-hours reaction suggests the market had already priced in these mixed results, but the longer-term downtrend in the stock price reflects ongoing caution.
For more detailed earnings data and analyst estimates, visit Venus Concept’s earnings page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.
NASDAQ:VERO (8/14/2025, 4:30:02 PM)
2.45
+0.01 (+0.41%)
Find more stocks in the Stock Screener